1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Reperfusion Injury - Pipeline Review, H1 2014

Reperfusion Injury - Pipeline Review, H1 2014

  • June 2014
  • -
  • Global Markets Direct
  • -
  • 72 pages

Reperfusion Injury - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Reperfusion Injury - Pipeline Review, H1 2014’, provides an overview of the Reperfusion Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reperfusion Injury and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Reperfusion Injury
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Reperfusion Injury and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Reperfusion Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Reperfusion Injury pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Reperfusion Injury
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Reperfusion Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Reperfusion Injury - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Reperfusion Injury Overview 8
Therapeutics Development 9
Pipeline Products for Reperfusion Injury - Overview 9
Pipeline Products for Reperfusion Injury - Comparative Analysis 10
Reperfusion Injury - Therapeutics under Development by Companies 11
Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes 13
Reperfusion Injury - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Reperfusion Injury - Products under Development by Companies 18
Reperfusion Injury - Products under Investigation by Universities/Institutes 19
Reperfusion Injury - Companies Involved in Therapeutics Development 20
NeuroVive Pharmaceutical AB 20
Scynexis, Inc. 21
Apeptico Forschung und Entwicklung GmbH 22
Stealth Peptides Inc. 23
Eustralis Pharmaceuticals Ltd 24
Nyken BV 25
Vasade Biosciences, Inc. 26
Reperfusion Injury - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
cyclosporine - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
MTP-131 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
GNX-5086 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
bucillamine - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Recombinant Protein to Inhibit CXCL for Cardiovascular and CNS Disorders - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
EUC-002 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
AP-301 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
NYK-1112 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Type 5 Adenylyl Cyclase Inhibitors - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Small Molecule for Reperfusion Injury - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
MitoSNO - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
PVIIA - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
RIIIK - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Small Molecules to Inhibit Cyclophilin D for Ischemia Reperfusion Injury, Neurodegenerative Diseases, And Trauma - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Synthetic Peptides to Activate Complement C3 for Immunology, Cardiovascular and CNS Disorders - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Reperfusion Injury - Recent Pipeline Updates 55
Reperfusion Injury - Dormant Projects 60
Reperfusion Injury - Discontinued Products 62
Reperfusion Injury - Product Development Milestones 63
Featured News and Press Releases 63
Feb 17, 2014: NeuroVive Treats Final Patient in European Phase III Trial on CicloMulsion 63
Aug 27, 2013: Congenia Announces Enrollment of First Healthy Volunteer in Phase 1 63
Jun 12, 2013: NeuroVive's Asian Subsidiary Receives First Milestone Payment From Sihuan Pharma 64
May 29, 2013: NeuroVive Provides Update On Ongoing Phase III Study Of CicloMulsion For Treatment Of Reperfusion Injury 64
May 27, 2013: New Chemical Compound Could Protect From Post-Heart Attack Tissue Damage, Researchers Report 65
Dec 03, 2012: NeuroVive Pharma Announces Publication Of Phase I Clinical Trial Of CicloMulsion In Clinical Drug Investigation 66
Dec 12, 2011: Pharming Receives US Patent On C1 Inhibitor Use In Ischemia Reperfusion Injury Indication 67
Nov 28, 2011: Stealth Peptides Announces Presentation Of Data On Bendavia At 2011 American Heart Association Annual Meeting 68
Nov 15, 2011: Researchers Present Promising Bendavia Findings At Annual American Society Of Nephrology Meeting 69
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 72
Disclaimer 72

List of Tables

Number of Products under Development for Reperfusion Injury, H1 2014 9
Number of Products under Development for Reperfusion Injury - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Development, H1 2014 17
Products under Development by Companies, H1 2014 18
Products under Investigation by Universities/Institutes, H1 2014 19
Reperfusion Injury - Pipeline by NeuroVive Pharmaceutical AB, H1 2014 20
Reperfusion Injury - Pipeline by Scynexis, Inc., H1 2014 21
Reperfusion Injury - Pipeline by Apeptico Forschung und Entwicklung GmbH, H1 2014 22
Reperfusion Injury - Pipeline by Stealth Peptides Inc., H1 2014 23
Reperfusion Injury - Pipeline by Eustralis Pharmaceuticals Ltd, H1 2014 24
Reperfusion Injury - Pipeline by Nyken BV, H1 2014 25
Reperfusion Injury - Pipeline by Vasade Biosciences, Inc., H1 2014 26
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 32
Number of Products by Stage and Route of Administration, H1 2014 34
Number of Products by Stage and Molecule Type, H1 2014 36
Reperfusion Injury Therapeutics - Recent Pipeline Updates, H1 2014 55
Reperfusion Injury - Dormant Projects, H1 2014 60
Reperfusion Injury - Dormant Projects (Contd..1), H1 2014 61
Reperfusion Injury - Discontinued Products, H1 2014 62

List of Figures

Number of Products under Development for Reperfusion Injury, H1 2014 9
Number of Products under Development for Reperfusion Injury - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Products, H1 2014 17
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 32
Number of Products by Top 10 Route of Administration, H1 2014 33
Number of Products by Stage and Top 10 Route of Administration, H1 2014 34
Number of Products by Top 10 Molecule Type, H1 2014 35
Number of Products by Stage and Top 10 Molecule Type, H1 2014 36

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

  • $ 4995
  • Industry report
  • October 2016
  • by GBI Research

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth Summary Cardiovascular disease (CVD) covers a range of difference ...

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Peripheral Arterial ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.